Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 3/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19770368 | 0.89 | TSHR (0.34) | PIK3R1PIK3CAMTORACHEDHFR | |
| SCHEMBL19770366 | 0.89 | DHFR (0.38) | PIK3CADHFRFGFR1 | |
| SCHEMBL19770359 | 0.85 | KDM4E (0.35) | PIK3R1PIK3CAMTORACHEHSP90AA1 | |
| SCHEMBL19770364 | 0.76 | HTT (0.33) | RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17963621 | 0.76 | MAPT (0.36) | DHFRFGFR1LMNAMAPT | |
| SCHEMBL21125475 | 0.75 | TSHR (0.34) | LMNAMAPT | |
| SCHEMBL17963639 | 0.74 | TSHR (0.34) | PIK3CADHFRHSP90AA1LMNAMAPT | |
| SCHEMBL17963641 | 0.71 | MAPT (0.42) | DHFRMAPT | |
| SCHEMBL20799377 | 0.71 | DHFR (0.41) | DHFRMAPT | |
| SCHEMBL20712621 | 0.66 | ADORA1 (0.36) | PIK3CADHFRRAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180015052-A1 | DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY | UNIV MARYLAND (US) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180015052-A1 | DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY | RNGTT, ACE, ADAR | PIK3R1 3763/4885PIK3CA 1848/4885MTOR 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.